Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

Abstract

BACKGROUND: The combination of immuno-oncology (IO) agents ipilimumab and nivolumab (IPI-NIVO) and vascular endothelial growth factor targeted therapies (VEGF-TT) combined with IO (IO-VEGF) are current standard of care first-line treatments for metastatic renal cell carcinoma (mRCC). OBJECTIVE: To establish real-world clinical benchmarks for IO combination therapies based on the International mRCC Database Consortium (IMDC) criteria.

Authors

Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS

Journal

European Urology, Vol. 84, No. 1, pp. 109–116

Publisher

Elsevier

Publication Date

July 2023

DOI

10.1016/j.eururo.2023.01.001

ISSN

0302-2838

Associated Experts

Aly-Khan Lalani

Associate Professor, Faculty of Health Sciences

Visit profile

Labels